title: Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach.
authors.affiliation: Department of Biostatistics and Medical Informatics and CINTESIS, Centre for Research in Health Technologies and Information Systems, Faculty of Medicine, Oporto University, Portugal. lazevedo@med.up.pt
authors.forename: L F
authors.initials: LF
authors.lastname: Azevedo
authors.forename: F
authors.initials: F
authors.lastname: Magro
authors.forename: F
authors.initials: F
authors.lastname: Portela
authors.forename: P
authors.initials: P
authors.lastname: Lago
authors.forename: J
authors.initials: J
authors.lastname: Deus
authors.forename: J
authors.initials: J
authors.lastname: Cotter
authors.forename: I
authors.initials: I
authors.lastname: Cremers
authors.forename: A
authors.initials: A
authors.lastname: Vieira
authors.forename: P
authors.initials: P
authors.lastname: Peixe
authors.forename: P
authors.initials: P
authors.lastname: Caldeira
authors.forename: H
authors.initials: H
authors.lastname: Lopes
authors.forename: R
authors.initials: R
authors.lastname: Gonçalves
authors.forename: J
authors.initials: J
authors.lastname: Reis
authors.forename: M
authors.initials: M
authors.lastname: Cravo
authors.forename: L
authors.initials: L
authors.lastname: Barros
authors.forename: P
authors.initials: P
authors.lastname: Ministro
authors.forename: M
authors.initials: M
authors.lastname: Lurdes
authors.forename: A
authors.initials: A
authors.lastname: Duarte
authors.forename: M
authors.initials: M
authors.lastname: Campos
authors.forename: L
authors.initials: L
authors.lastname: Carvalho
authors.forename: A
authors.initials: A
authors.lastname: Costa-Pereira
mesh_terms: D000328:Adult; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology*; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010349:Patient Compliance / Q000706:statistics & numerical data; D017891:Pharmacoepidemiology / Q000379:methods* / Q000706:statistics & numerical data; D011174:Portugal / Q000453:epidemiology; D015995:Prevalence; D012737:Sex Factors; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D012460:Sulfasalazine; D019804:Mesalamine